

# 23rd Pharmacovigilance 2020

#VIphv

“Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management”

16th December 2020, Virtual Conference (Time Zone - IST)

## AGENDA AT A GLANCE

## Key Speakers Include



**BABITA KIRODIAN**  
Country Pharmacovigilance Lead  
Amgen



**S.SALAVADI EASWARAN**  
Academic Dean  
Biocon Academy



**ARUN BHATT**  
Consultant - Clinical Research & Development



**OMPRAKASH S. SADHWANI**  
Former Joint Commissioner and controlling Authority, FDA (Maharashtra state)



**INDU NAMBIAR**  
Head Pharmacovigilance  
Boehringer Ingelheim



**S.R.SALUNKHE**  
Former Assistant commissioner  
FDA Maharashtra



**MANOJ SWAMINATHAN**  
Chief Manager / Head - Global  
Pharmacovigilance Center, Piramal



**JAMAL BAIG**  
Country Head- Pharmacovigilance  
Merck Sharp & Dohme



**RANJIT BARSHIKAR**  
QbD / CGMP Consulting, Member Editorial  
Board Journal of Generic Medicines, England



**PAVAN BADALE**  
Head- PV Process Excellence, Safety case  
Management, Novartis



**DHANARAJ E**  
Pharmacovigilance Lead  
Biocon



**JYOTSNA PATWARDHAN**  
Head Development QA  
Novartis



**SAKHARAM GARALE**  
Head South-East Asia Operations ACMA &  
Managing Partner, **RENOVARE Healthcare Solutions**



**KAVYA KADAM**  
Consultant Global Clinical Trials

Plus more COMING SOON.....

SUPPORTED BY



Organized by



+91 44 42108101

info@virtueinsight.com

# 23rd Pharmacovigilance 2020

#VIphv

“Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management”

16th December 2020, Virtual Conference (Time Zone - IST)

## AGENDA AT A GLANCE

### CONFERENCE INTRODUCTION

Virtue insight's 23rd Pharmacovigilance Conference is more than a traditional conference. It is a unique opportunity to learn about the latest trends, to engage with renowned experts, and to personally develop as a healthcare professional. The **23rd Pharmacovigilance Conference** will take place virtually for the very first time on **16th December 2020**.

This conference provides the foundation for strong strategic planning and practical decision-making in your pharmacovigilance programs. This year's conference will address the current thinking on predicting and assessing risks such as drug-induced liver injury, and the assessment of expectedness of serious adverse reactions during clinical development. The complexities of assessing benefit-risk balance of today's therapies, including immunotherapy and other advanced therapies, will be examined. Experts will present approaches and engage in dialogs around more extensive and impactful uses of real world data and generation of RWE for safety assessments. A full-day will be devoted to the development, implementation, and assessment of risk management strategies for drugs approved in multiple regions.

Take the opportunity to learn from regulators and leading experts and discover what the challenges and opportunities will be in the field of Pharmacovigilance in 2020.

Do not miss out on these exciting discussions. Join us virtually to discover and learn from the experts who will be joining us on 16th December 2020.

We look forward to seeing you there!

### KEY THEMES DISCUSSED

- Review, predictions & updates on the global pharmacovigilance market
- Key regulations and pharmacovigilance system
- Pharmacovigilance and its importance in the pharmaceutical industry expands
- Discussion of pharmacovigilance and its effect in healthcare and patient care
- Demand for pharmacovigilance and consumer research
- Addressing concerns with drug safety by recognizing the risks associated with pharmaceutical products and reducing the possibility of any potential harm to patients
- Present legislation and proposals for pharmaceutical drugs endorse and carry out post marketing drug tests
- Planning pharmacovigilance and risk management
- Concentrating on the pharmacovigilance regulatory system in the form of risk management planning
- A performance risk management strategy across the drug development lifecycle
- The complexities of communicating and controlling the established quality risks
- Addressing global perspective of pharmacovigilance and risk management strategies
- Discussing about improving health outcomes and patient safety
- Real world evidence: The evolving regulatory landscape, information and integrated usage
- How real-world data is used today to produce evidence in major markets
- A new approach and support towards pharmacovigilance regulations
- New regulatory guidelines and laws governing pharmacovigilance
- Be part of a major networking opportunity

### WHO SHOULD ATTEND AND WHO YOU'LL MEET

**Vice Presidents, Directors, CRO's, Heads and Managers of:**

Pharmacovigilance Strategy, Drug Safety/Risk Management, Information and Clinical Data Management, Clinical Research, Research & Development, Product Safety/Assurance Assessment, Patient Safety & Outcomes Research & Data Analysis, Epidemiology project management, Regulatory Affairs and Compliance, Sales & Marketing, Biotech manufacturers

**From the following :**

Pharmaceutical organizations, Generic pharmaceutical companies, Contract research organizations, Patient recruitment companies, Government- Department of health, Non-profit organizations/ Association, Consultants

Organized by



+91 44 42108101

info@virtueinsight.com

# 23rd Pharmacovigilance 2020

#VIphv

“Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management”

16th December 2020, Virtual Conference (Time Zone - IST)

## AGENDA AT A GLANCE

### DAY ONE - 16th December 2020

09:20 - Chairperson opening remarks

**RANJIT BARSHIKAR**  
QbD / CGMP Consulting, Member Editorial Board Journal of Generic Medicines, England

#### MARKET OVERVIEW & ANALYSIS

09:30 - Discussion of the demand for pharmacovigilance and consumer research

- Review and predictions on the global pharmacovigilance market
- Global pharmacovigilance, drug safety, market size growth, and revenue analysis
- Addressing the recent financial developments while analysing the growth of the key market players
- Total review of current and emerging trends and opportunities

10:00 - Discussing updates on pharmacovigilance in India

- Key regulations and pharmacovigilance system
- Current Pharmacovigilance conditions and requirements in India
- Understanding the important issues that need to be addressed
- Main problems to tackle when implementing systems and choosing vendors

10:30 - Morning Coffee/Tea & Discussion

#### CHALLENGES & OPPORTUNITIES

10:50 - DISCUSSION WITH EXPERTS: Pharmacovigilance and its importance in the pharmaceutical industry expands

- Discussion of pharmacovigilance and its effect in healthcare and patient care
- Pharmacovigilance laws and a view on the laws and restrictions to be observed in pharmacovigilance
- Discussing on pharmaceutical industry problems in developing pharmacovigilance networks
- Scientific discussion in the field of pharmacovigilance in herbal medicines

- Detection and assessment of drug safety signals via reporting by manual and medical devices
- Challenges of improving drug protection and maintaining public trust

Moderator:

**DHANARAJ E**  
Pharmacovigilance Lead  
Biocon

Panellists:

**BABITA KIRODIAN**  
Country Pharmacovigilance Lead  
Amgen

**JAMAL BAIG**  
Country Head- Pharmacovigilance  
Merck Sharp & Dohme

**MANOJ SWAMINATHAN**  
Chief Manager / Head - Global Pharmacovigilance Center, Piramal

**INDU NAMBIAR**  
Head Pharmacovigilance  
Boehringer Ingelheim

11:30 - DISCUSSION WITH EXPERTS: Addressing concerns with drug safety by recognizing the risks associated with pharmaceutical products and reducing the possibility of any potential harm to patients

- Present legislation and proposals for pharmaceutical drugs endorse and carry out post-marketing drug tests
- Addressing the safety issues contained in the risk management program and regular steps to reduce potential risks.
- Address safety issues regarding drug errors and risk minimization measures in India for centrally approved products
- Addressing drug safety issues which includes the development of tools, techniques, and data sources that helps to better identifying and managing safety issues related to drug effects and product quality
- Develop new and creative methods to enhance the capabilities of testing drug products.
- Discussing and applying complex data to identify safety and effectiveness concerns and support informed decision-making

Organized by



+91 44 42108101

info@virtueinsight.com

# 23rd Pharmacovigilance 2020

#VIphv

“Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management”

16th December 2020, Virtual Conference (Time Zone - IST)

## AGENDA AT A GLANCE

### DAY ONE - 16th December 2020

Moderator:

**RANJIT BARSHIKAR**  
QbD / CGMP Consulting, Member Editorial Board Journal of Generic Medicines, England

Panellists:

**OMPRAKASH S. SADHWANI**  
Former Joint Commissioner and controlling Authority, Food and Drug Administration (Maharashtra state)

**S.R.SALUNKHE**  
Former Assistant commissioner  
FDA Maharashtra

**PAVAN BADALE**  
Head- PV Process Excellence, Safety case Management  
Novartis

**SAKHARAM GARALE**  
Head South-East Asia Operations ACMA & Managing Partner, RENOVARE Healthcare Solutions

.....  
12:10 - Challenges of Clinical Trial Safety Management during a Pandemic

**ARUN BHATT**  
Consultant - Clinical Research & Development

.....  
12:40 - Networking luncheon

.....  
Afternoon Chair Person

.....  
13:50 - Applications of Artificial Intelligence Tools in Enhancing Decision Making in Pharmacovigilance Program

**S.SALAVADI EASWARAN**  
Academic Dean  
Biocon Academy

14:20 - DISCUSSION WITH EXPERTS: Addressing global perspective of pharmacovigilance and risk management strategies

- Discussing about improving health outcomes and patient safety
- Approaches when managing drug benefits and risks
- Additional measures other than product labeling while communicating a risk or influencing a health care provider and patient behavior
- Addressing the risk reduction approaches that various regulatory agencies accept
- Identify situations where the REMS and the risk management programs vary in compliance
- Discuss approaches for risk management which have been effectively applied in a dynamic global context

Moderator:

Panellists:

**JYOTSNA PATWARDHAN**  
Head Development QA  
Novartis

**KAVYA KADAM**  
Consultant Global Clinical Trials

.....  
15:10 - Afternoon Tea/Coffee

.....  
15:30 - Real world evidence: The evolving regulatory landscape, information and integrated usage

- How real-world data is used today to produce evidence in major markets
- Concentrating on generating facts for regulatory use
- Whether the reliability of proof from real-world data for every use case is evaluated
- Current status of FDA guidance

.....  
16:00 - DISCUSSION WITH EXPERTS: A new approach and support towards pharmacovigilance regulations

- New regulatory guidelines and laws governing pharmacovigilance

Organized by



+91 44 42108101

info@virtueinsight.com

# 23rd Pharmacovigilance 2020

#VIphv

“Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management”

16th December 2020, Virtual Conference (Time Zone - IST)

## AGENDA AT A GLANCE

### DAY ONE - 16th December 2020

- Discussion of the directives and regulations which constitute the greatest shift in the regulation of human medicine
- Post-authorisation regulatory standards that must be adhered by the applicant to ensure compliance with the FDA
- Focusing on the need to refine Pharmacovigilance regulatory standards in India
- Maintain close relations with drug regulatory authority to ensure that the latter are well educated in regular clinical practice about safety issues

**Moderator:**

**Panellists:**

.....

17:40 - Chairperson's closing remarks and end of conference

.....

Organized by



+91 44 42108101

info@virtueinsight.com

# 23rd Pharmacovigilance 2020

#VIphv

“Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management”


16th December 2020, Virtual Conference (Time Zone - IST)

AGENDA  
AT A GLANCE

## Features of our Virtual Conference

### NETWORKING

**Lobby** – Here at the lobby, all attendees can see the other participants. You can choose to start a conversation privately at any time with any of the other co-participants– For more details – check out the links (YouTube videos in the last page)



Organized by



+91 44 42108101

info@virtueinsight.com

# 23rd Pharmacovigilance 2020


#VIphv

“Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management”


16th December 2020, Virtual Conference (Time Zone - IST)

## AGENDA AT A GLANCE

**Reception** – Should you have any questions to the organisers, you can find them at the reception - For more details – check out the links (YouTube videos in the last page)



**Q&A, Polls & Handouts**– We can have Q&A from the audience at the end of every session as usual and also have polls and handouts done - For more details – check out the links (YouTube videos in the last page)



Organized by



+91 44 42108101

info@virtueinsight.com

# 23rd Pharmacovigilance 2020

#VIphv

“Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management”

16th December 2020, Virtual Conference (Time Zone - IST)

AGENDA  
AT A GLANCE


## LIVE STREAMING

**Solo Presentations & Panel Sessions**– Interactive panel sessions and solo presentations sessions - For more details – check out the links (YouTube videos in the last page)



## SPONSORS & EXHIBITORS

**Exhibitors**– Exhibitors have booths where they can start a conversation with any of the attendees and also attend to the attendees who visit their stall - For more details – check out the links (YouTube videos in the last page)



Organized by



+91 44 42108101

info@virtueinsight.com



# 23rd Pharmacovigilance 2020

#VIphv

“Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management”

16th December 2020, Virtual Conference (Time Zone - IST)

## AGENDA AT A GLANCE



**Sponsors**– Sponsors can have speaking slot sessions and their logos would be visible in all sessions for their branding purposes - For more details – check out the links (YouTube videos in the last page)



Links to YouTube videos of the conference webinar platform

**Live Event Walkthrough** - <https://www.youtube.com/watch?v=KRX5j3gQeF0>

**Exhibitor Instructions** - <https://www.youtube.com/watch?v=uOvH46TeYrw>

**Visitor Instructions** - <https://www.youtube.com/watch?v=c4WSfp9RFP0>

Organized by



+91 44 42108101

info@virtueinsight.com

# 23rd Pharmacovigilance 2020

#VIphv

“Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management”

16th December 2020, Virtual Conference (Time Zone - IST)

## AGENDA AT A GLANCE

### REGISTER ONLINE :

Link : <https://www.bookmytrainings.com/catalogue/event/78986-23rd-pharmacovigilance-2020>

For Multiple Bookings - Photocopy this form and send it to [bookings@virtueinsight.com](mailto:bookings@virtueinsight.com)

### REGISTRATION FORM

#### RESERVATION PRICING:

##### Early Bird Discount Price

Cost per delegate (Valid till 15th November 2020) -

Fee: INR 07,000 + GST(18%)

##### Standard Rate

Cost per delegate (Valid From 16th November 2020)-

Fee: INR 10,000 + GST(18%)

##### Discounted Rate for Bulk Booking of More Than 5 Delegates

Please email us at [bookings@virtueinsight.com](mailto:bookings@virtueinsight.com)

##### Registration Form Details:

Forename .....Surname .....

Job Title .....

Company .....

GST No (If Applicable) .....

Official Contact Number .....

Address .....

Country .....Postcode.....

Phone .....Fax .....

Email .....

I confirm that I have read & agree to the terms and conditions of booking.... (Please Tick)

Signature .....

##### Methods of Payments:

**By Cheque** - Complete and return the above registration form via post or email, together with your cheque payable to Virtue Insight.

##### By Bank Transfer:

Account Name - Virtue Insight  
Account Type - Current  
Account Number - 915020031763553  
Bank Name - Axis Bank  
Bank Address - 2/8 LAMBERT NAGAR, 1st cross street,  
Virugambakkam, Chennai - 600 092  
Branch Name - Virugambakkam, Chennai  
Swift Code - AXISINBB211  
NEFT / IFSC Code - UTIB0000211  
Micro Code - 600211010

### CERTIFICATION

E-Certificate of attendance would be provided to attendees on request, upon completion of conference

#### Queries:

Should you have any questions on bookings, Please feel free to contact us.

Email: [info@virtueinsight.com](mailto:info@virtueinsight.com)  
Web: <http://www.virtueinsight.com>  
India Office; Tel: +91 44 42108101  
UK Office; Tel: +44-20 3509 3779

#### TERMS AND CONDITIONS:

**Payment terms:** Virtue Insight requires the full amount to be paid before the conference. We may refuse entry to delegates who have not paid their invoice in full.

**Cancellations:** Delegates and vendors are subject to the following charges and refunds upon withdrawal or cancellation between 2-3 month's prior 75% cancellation fee/ 25% refund. Less than 2 months prior to the event Full cancellation fee / No refund.

**Administration Fee:** If you cancel your participation (once confirmed) and haven't paid the attendance fee you will be liable to pay an administration fee of INR 5,000

**Substitutions/Name Change:** If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. This can be done at no extra cost.

**Indemnity:** Virtue Insight reserves the right to make alterations to the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to unforeseen events beyond the control of Virtue Insight. If such a situation arises, we will reschedule the event.

Organized by



+91 44 42108101

[info@virtueinsight.com](mailto:info@virtueinsight.com)